AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29057120 — intervention group
Group type: COMPARATOR
Intervention: Discordant fluid management (Group 2)
Number of subjects: 33
Study 29057273 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS)
Number of subjects: 400
Study 29057273 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve dysfunction
Number of subjects: 400
Study 29057273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiposity
Number of subjects: 400
Study 29058553 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-support treadmill training (BWSTT) program
Number of subjects: 17
Study 29058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sepsis in ICU patients
Number of subjects: 35
Study 29058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sepsis in rats
Number of subjects: 35
Study 29058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem human brains from sepsis nonsurvivors
Number of subjects: 35
Study 29058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem rat brains
Number of subjects: 35
Study 29058589 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from sepsis onset
Number of subjects: 35
Study 29058603 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of spirituality and religion into community-based physical activity programs
Number of subjects: 23
Study 29058601 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosing of meropenem
Number of subjects: 48
Study 29058601 — intervention group
Group type: EXPERIMENTAL
Intervention: MeroRisk Calculator (tool for assessing risk)
Number of subjects: 48
Study 29058632 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement-oriented restorative care (MRC)
Number of subjects: 61
Study 29058632 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 61
Study 29058816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bosutinib (100 mg × 5)
Number of subjects: 14
Study 29058816 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bosutinib (120 mg in approximately 240 mL over 1 hour)
Number of subjects: 14
Study 29059387 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental perceptions of tobacco smoke exposure
Number of subjects: 65
Study 29059387 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental misconceptions about tobacco smoke exposure
Number of subjects: 65
Study 29059387 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental awareness of child exposure to tobacco smoke
Number of subjects: 65
Study 29059387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory perceptions used by parents
Number of subjects: 65
Study 29059387 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific information provided to parents
Number of subjects: 65
Study 29059466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 83
Study 29059466 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein values and increase of >10% in liver stiffness after TIPS
Number of subjects: 83
Study 29059466 — intervention group
Group type: COMPARATOR
Intervention: Shear wave elastography of liver and spleen
Number of subjects: 83
Study 29060496 — intervention group
Group type: EXPERIMENTAL
Intervention: New FoG-detection method using temporal, spatial, and physiological features with a support-vector-machine classifier.
Number of subjects: 0
Study 29060496 — intervention group
Group type: COMPARATOR
Intervention: Energy-based detection method.
Number of subjects: 0
Study 29061603 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tool for improving access to financial benefits
Number of subjects: 0
Study 29061725 — intervention group
Group type: EXPERIMENTAL
Intervention: Central ambulatory systolic pressure measured with a validated oscillometric device
Number of subjects: 289
Study 29061725 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial ambulatory systolic pressure
Number of subjects: 289
Study 29061725 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial office blood pressure
Number of subjects: 289
Study 29061725 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass determined by echocardiography
Number of subjects: 289
Study 29062240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine regimen A (1.5/0.10 mg)
Number of subjects: 200
Study 29062240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine regimen B (1.5/0.35 mg)
Number of subjects: 200
Study 29062240 — intervention group
Group type: COMPARATOR
Intervention: Morphine (4.0/1.0 mg)
Number of subjects: 200
Study 29062240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29062524 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision guide for elderly care decision-making
Number of subjects: 0
Study 29063494 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter left gastric artery embolization (LGAE)
Number of subjects: 5
Study 29063805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 110
Study 29063805 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomeres
Number of subjects: 110
Study 29063814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD; Epidiolex; Greenwich Biosciences)
Number of subjects: 3
Study 29064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium (diagnosed using confusion assessment method)
Number of subjects: 726
Study 29064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium (prevalent and incident)
Number of subjects: 726
Study 29064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium (overall and prevalent)
Number of subjects: 726
Study 29064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium (overall, incident, or prevalent)
Number of subjects: 726
Study 29064263 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive confusion assessment method
Number of subjects: 726
Study 29064349 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan monotherapy for 16 weeks
Number of subjects: 100
Study 29064349 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on sildenafil for an additional 12 weeks
Number of subjects: 100
Study 29064349 — intervention group
Group type: EXPERIMENTAL
Intervention: cMRI-derived parameters
Number of subjects: 100
Study 29064772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 38
Study 29064927 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal distension stimulations in patients with IBS
Number of subjects: 0
Study 29064927 — intervention group
Group type: COMPARATOR
Intervention: Rectal distension stimulations in healthy controls
Number of subjects: 0
Study 29065747 — intervention group
Group type: EXPERIMENTAL
Intervention: Total marrow irradiation (TMI)
Number of subjects: 0
Study 29065747 — intervention group
Group type: COMPARATOR
Intervention: Intravenous melphalan
Number of subjects: 0
Study 29065865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 to 10 μg twice a day for 20 weeks
Number of subjects: 71
Study 29065865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 71
Study 29065892 — intervention group
Group type: EXPERIMENTAL
Intervention: Eotaxin
Number of subjects: 3239
Study 29065892 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 3239
Study 29065892 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 3239
Study 29065892 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2, IL-6, IL-8, eotaxin
Number of subjects: 3239
Study 29065892 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL17
Number of subjects: 3239
Study 29065923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon (IGB) treatment for 6 months
Number of subjects: 50
Study 29065931 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic sacroiliitis (measured by sacroiliitis sum score between 0 and 8)
Number of subjects: 210
Study 29065955 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0
Study 29065956 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative hyperpnea pattern
Number of subjects: 33
Study 29065956 — intervention group
Group type: COMPARATOR
Intervention: Positive hyperpnea pattern
Number of subjects: 33
Study 29066389 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-PD15 (total lung capacity-adjusted lung density)
Number of subjects: 3390
Study 29066389 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline in TLC-PD15
Number of subjects: 3390
Study 29066505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-AKT Inhibitor AZD5363
Number of subjects: 0
Study 29066590 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Pulmonary Rehabilitation (PR) program including a computer tablet, activity monitor, and oximeter, with 12 min of walking and 6 full-body exercises, completed 6 days/week, plus weekly telephone calls with the PR health coach.
Number of subjects: 0
Study 29067298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene (oral administration for 3 days)
Number of subjects: 9
Study 29067298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral administration for 3 days)
Number of subjects: 9
Study 29067304 — intervention group
Group type: EXPERIMENTAL
Intervention: Aducanumab (0.3, 1, 3, 10, 20, 30, and 60 mg/kg)
Number of subjects: 8
Study 29067304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29067328 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured conversations with standardized preselected topics
Number of subjects: 41
Study 29067328 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic features obtained by LIWC
Number of subjects: 41
Study 29067332 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-311 (synthetic peptide vaccine)
Number of subjects: 0
Study 29067347 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices hearing intervention
Number of subjects: 40
Study 29067347 — intervention group
Group type: COMPARATOR
Intervention: Successful aging intervention
Number of subjects: 40
Study 29067643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gedatolisib (PF-05212384) with Irinotecan 180 mg/m
Number of subjects: 0
Study 29067643 — intervention group
Group type: COMPARATOR
Intervention: PF-04691502
Number of subjects: 0
Study 29067643 — intervention group
Group type: COMPARATOR
Intervention: Gedatolisib (PF-05212384) with PD-0325901
Number of subjects: 0
Study 29067643 — intervention group
Group type: COMPARATOR
Intervention: PF-04691502 with PD-0325901
Number of subjects: 0
Study 29067842 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared reading
Number of subjects: 282
Study 29067842 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 282
Study 29067842 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 282
Study 29068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day) as monotherapy or adjunctive therapy
Number of subjects: 811
Study 29068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (higher than recommended doses)
Number of subjects: 811
Study 29068794 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR as adjunctive therapy to antidepressants
Number of subjects: 811
Study 29069114 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant calcium channel blocker (CCB) plus antipsychotic (AP) therapy
Number of subjects: 0
Study 29069114 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic (AP) therapy alone
Number of subjects: 0
Study 29070010 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice-daily for 1 year
Number of subjects: 72
Study 29070480 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered dialectical behavior therapy (DBT) skills training, 8-week intervention
Number of subjects: 60
Study 29070480 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 60
Study 29070555 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 29070559 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 29070638 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexually identified MSM
Number of subjects: 600
Study 29070641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Population Risk Tool (DemPoRT)
Number of subjects: 44052
Study 29070939 — intervention group
Group type: EXPERIMENTAL
Intervention: palucorcel (CNTO 2476) administered subretinally at a targeted dose of 3.0×10
Number of subjects: 7
Study 29070939 — intervention group
Group type: EXPERIMENTAL
Intervention: palucorcel (CNTO 2476)
Number of subjects: 7
Study 29070939 — intervention group
Group type: EXPERIMENTAL
Intervention: alternative subretinal delivery methods for palucorcel
Number of subjects: 7
Study 29071072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT) during exercise tests
Number of subjects: 0
Study 29071072 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control) during exercise tests
Number of subjects: 0
Study 29071072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT)
Number of subjects: 0
Study 29071077 — intervention group
Group type: EXPERIMENTAL
Intervention: BreatheSmart mobile technology (wireless Bluetooth-enabled inhaler sensors and mSpirometer)
Number of subjects: 100
Study 29071087 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 10 mg
Number of subjects: 99
Study 29071087 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-8500a 75 mg
Number of subjects: 99
Study 29071087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 29071091 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard system with weight-adjusted intravenous furosemide
Number of subjects: 10
Study 29071091 — intervention group
Group type: EXPERIMENTAL
Intervention: RenalGuard system
Number of subjects: 10
Study 29071264 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation of the IMA
Number of subjects: 100
Study 29071264 — intervention group
Group type: COMPARATOR
Intervention: Low ligation of the IMA
Number of subjects: 100
Study 29071307 — intervention group
Group type: EXPERIMENTAL
Intervention: Original, intensive STOMP protocol (3 hours/day, 5 days/week for 2 weeks)
Number of subjects: 32
Study 29071307 — intervention group
Group type: COMPARATOR
Intervention: Less-intensive STOMP protocol (1 hour/day, 2 days/week for 2 weeks)
Number of subjects: 32
Study 29071793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (140% caloric intake, 44% from fat) for 8 weeks
Number of subjects: 29
Study 29071802 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 65
Study 29071802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise + Weight Loss (AEX + WL)
Number of subjects: 65
Study 29072473 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PTS symptoms
Number of subjects: 697
Study 29072473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrusion symptoms
Number of subjects: 697
Study 29072772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib treatment in CP2L cohort
Number of subjects: 403
Study 29072772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib treatment in CP3L cohort
Number of subjects: 403
Study 29072772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic diarrhea in CP2L cohort
Number of subjects: 403
Study 29072772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic diarrhea in CP3L cohort
Number of subjects: 403
Study 29072975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
Number of subjects: 16
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS (self-reported)
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage category of LUTS
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding category of LUTS
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-micturition category of LUTS
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than median HAQ DI in storage category
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher than median HAQ DI for digestive symptoms burden in voiding category
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis in voiding category
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive symptoms burden in post-micturition category
Number of subjects: 334
Study 29073343 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL)
Number of subjects: 334
Study 29073362 — intervention group
Group type: EXPERIMENTAL
Intervention: Early implant placement with simultaneous contour augmentation through guided bone regeneration with a 2-layer composite graft
Number of subjects: 20
Study 29073584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 mg/d
Number of subjects: 1215
Study 29074030 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert CT/NG Assay (Cepheid, Sunnyvale, CA) using a urine sample
Number of subjects: 1162
Study 29074030 — intervention group
Group type: COMPARATOR
Intervention: Aptima Combo 2 Assay (Gen-Probe Incorporated, San Diego, CA) using a swab sample
Number of subjects: 1162
Study 29074183 — intervention group
Group type: EXPERIMENTAL
Intervention: BD Onclarity HPV assay
Number of subjects: 276
Study 29074183 — intervention group
Group type: COMPARATOR
Intervention: HC2
Number of subjects: 276
Study 29074183 — intervention group
Group type: COMPARATOR
Intervention: Onclarity
Number of subjects: 276
Study 29074183 — intervention group
Group type: COMPARATOR
Intervention: LA
Number of subjects: 276
Study 29074187 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine (9vHPV)
Number of subjects: 10706
Study 29074187 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vaccine HPV types (35/39/51/56/59)
Number of subjects: 10706
Study 29074187 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 10706
Study 29074501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/d until progression or intolerance
Number of subjects: 40
Study 29074512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing parameters measured at term-equivalent age in EP-born infants
Number of subjects: 52
Study 29074512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing parameters
Number of subjects: 52
Study 29074512 — intervention group
Group type: COMPARATOR
Intervention: Healthy term-born infants (control group)
Number of subjects: 52
Study 29074518 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal neuromodulation device with three different stimulation parameter sets for 12 weeks
Number of subjects: 342
Study 29074518 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal neuromodulation device
Number of subjects: 342
Study 29074543 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to carcinogens
Number of subjects: 0
Study 29074543 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29075620 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs), specific dosage and duration not mentioned.
Number of subjects: 0
Study 29075620 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 29075855 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) monotherapy at 1.25 mg/kg intravenously every 2 weeks
Number of subjects: 66
Study 29076110 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (1-48 mg immediate-release doses)
Number of subjects: 572
Study 29076110 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (in RA patients)
Number of subjects: 572
Study 29076110 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (in RA patients with renal impairment)
Number of subjects: 572
Study 29076110 — intervention group
Group type: COMPARATOR
Intervention: Upadacitinib (compared to healthy volunteers)
Number of subjects: 572
Study 29077645 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Rite Cola, sweetened with 68-mg sucralose and 41-mg ace-K
Number of subjects: 34
Study 29077711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (4,000 IU/d for VDAART and 2,400 IU/d for COPSAC2010)
Number of subjects: 1387
Study 29077855 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training) - 12 weeks, 3 days per week of 4 × 4 minute intervals at over 90% of peak aerobic capacity (VO2peak) with 2 days per week of treadmill walking at 70% VO2peak.
Number of subjects: 27
Study 29077855 — intervention group
Group type: COMPARATOR
Intervention: SED (Sedentary Control) - 12 weeks, no exercise intervention.
Number of subjects: 27
Study 29077855 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training) - 12 weeks.
Number of subjects: 27
Study 29077855 — intervention group
Group type: COMPARATOR
Intervention: SED (Sedentary Control) - 12 weeks.
Number of subjects: 27
Study 29077908 — intervention group
Group type: EXPERIMENTAL
Intervention: LIN28B (rs7759938)
Number of subjects: 1478
Study 29077908 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHB c.-211G>T (rs10835638) and FSHR c.-29G>A (rs1394205) minor allele count
Number of subjects: 1478
Study 29077941 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) 0.5-1.5 mg/kg in combination with temozolomide (arm B)
Number of subjects: 38
Study 29077941 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin (depatux-m) 1.25 mg/kg as monotherapy (arm C)
Number of subjects: 38
Study 29077941 — intervention group
Group type: COMPARATOR
Intervention: Depatuxizumab mafodotin (depatux-m)
Number of subjects: 38
Study 29077963 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement System Impairment-Based Classification Treatment
Number of subjects: 0
Study 29077963 — intervention group
Group type: COMPARATOR
Intervention: General Exercises
Number of subjects: 0
Study 29078170 — intervention group
Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 570